Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria - Case Tissue:
Exclusion Criteria - Case Tissue:
Patient has received cancer treatment in the 5 years prior to TURBT/CBF.
Patient has had any prior radiation therapy (including brachytherapy therapy) to the target lesion prior to TURBT/CBF
Patient has a recurrent muscle invasive bladder cancer.
Exclusion – Cystectomy/Cystoprostatectomy
Patient has received cancer treatment in the 5 years prior to Cystectomy/Cystoprostatectomy.
Patient has had any prior radiation therapy (including brachytherapy therapy) to the target lesion prior to Cystectomy/Cystoprostatectomy.
Patient has a recurrent muscle invasive bladder cancer
Inclusion Criteria - Control Tissue:
Exclusion Criteria - Control Tissue:
Patient has received cancer treatment in the 5 years prior to Prostatectomy.
Patient has had any prior radiation therapy (including brachytherapy therapy) to the target tissue prior to Prostatectomy.
Patient has had bladder, urothelial or kidney cancer
Inclusion Criteria - Blood:
Exclusion Criteria - Blood:
Inclusion Criteria - Case Urine:
Age >18 years.
Patient has undergone office-based evaluation for hematuria (CT, ultrasound, cystoscopy)
Patient has a histological diagnosis of muscle invasive urothelial cell carcinoma of bladder.
Exclusion Criteria - Case Urine:
·Patient has known cancer outside of the target cancer 5 years prior to current collection (not including basal cell or squamous cell skin cancers; if patient has not been seen or if information is not available, the patient is eligible)
Patient has recurrent muscle invasive bladder cancer.
Patient has ever been previously diagnosed with UTUC (Upper Tract Urothelial Carcinoma) prior to bladder resection.
Patient has received chemotherapy class drugs for the treatment of non-target origin cancer in the 5 years prior to current collection.
Patient has had any prior radiation therapy to the target lesion prior to current collection.
Patient has had a biopsy to the target organ and/or lesion within 3 days before collection.
Patient has undergone cystectomy or cystoprostatectomy.
Patient has transurethral instrumentation (placement of urinary catheter) within 7 days prior to urine collection.
Patient has had a urinary tract infection within 14 days prior to urine collection.
Patient has chronic indwelling urinary catheter.
Inclusion Criteria - Disease Control Urine:
Exclusion Criteria - Disease Control Urine:
Patient has known cancer outside of the target cancer 5 years prior to current collection (not including basal cell or squamous cell skin cancers; if patient has not been seen or if information is not available, the patient is eligible.
Patient has recurrent muscle invasive bladder cancer.
Patient has ever been previously diagnosed with UTUC (Upper Tract Urothelial Carcinoma) prior to bladder resection.
Patient has received chemotherapy class drugs for the treatment of non-target origin cancer in the 5 years prior to current collection.
Patient has had any prior radiation therapy to the target lesion prior to current collection.
Patient has had a biopsy to the target organ and/or lesion within 3 days before collection.
Patient has undergone cystectomy or cystoprostatectomy.
Patient has transurethral instrumentation (placement of urinary catheter) within 7 days prior to urine collection.
Patient has had a urinary tract infection within 14 days prior to urine collection.
Patient has chronic indwelling urinary catheter .
Inclusion Criteria - Case Blood:
Age >18 years.
Patient has undergone office-based evaluation for hematuria (CT, ultrasound, cystoscopy)
Patient has a histological diagnosis of invasive urothelial cell carcinoma of bladder.
Exclusion Criteria - Case Blood:
Patient has known cancer outside of the target cancer 5 years prior to current collection (not including basal cell or squamous cell skin cancers; if patient has not been seen or if information is not available, the patient is eligible.
Patient has recurrent muscle invasive bladder cancer.
Patient has ever been previously diagnosed with UTUC (Upper Tract Urothelial Carcinoma) prior to bladder resection.
Patient has received chemotherapy class drugs for the treatment of non-target origin cancer in the 5 years prior to current collection.
Patient has had any prior radiation therapy to the target lesion prior to current collection.
Patient has had a biopsy to the target organ and/or lesion within 3 days before collection.
Patient has undergone cystectomy or cystoprostatectomy.
Inclusion Criteria - Disease Control Blood
Exclusion Criteria - Disease Control Blood
·Patient has known cancer outside of the target cancer 5 years prior to current collection (not including basal cell or squamous cell skin cancers; if patient has not been seen or if information is not available, the patient is eligible)
Patient has recurrent muscle invasive bladder cancer.
Patient has ever been previously diagnosed with UTUC (Upper Tract Urothelial Carcinoma) prior to bladder resection.
Patient has received chemotherapy class drugs for the treatment of non-target origin cancer in the 5 years prior to current collection.
Patient has had any prior radiation therapy to the target lesion prior to current collection.
Patient has had a biopsy to the target organ and/or lesion within 3 days before collection.
Patient has undergone cystectomy or cystoprostatectomy.
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 6/4/2025. Questions regarding updates should be directed to the study team contact.